Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:administeredBy |
moderate COVID-19 cases
severe COVID-19 cases |
| gptkbp:alsoKnownAs |
gptkb:CIGB-258
|
| gptkbp:approvalYear |
2021
|
| gptkbp:approvedBy |
gptkb:Cuba
|
| gptkbp:clinicalTrialPhase |
Phase III (as of 2023)
|
| gptkbp:composition |
peptide
|
| gptkbp:countryOfOrigin |
gptkb:Cuba
|
| gptkbp:derivedFrom |
heat shock protein 60 (HSP60)
|
| gptkbp:developedBy |
gptkb:Center_for_Genetic_Engineering_and_Biotechnology
|
| https://www.w3.org/2000/01/rdf-schema#label |
Jusvinza
|
| gptkbp:indication |
rheumatoid arthritis
COVID-19 cytokine storm |
| gptkbp:mechanismOfAction |
immunotherapy
|
| gptkbp:regulates |
emergency use authorization in Cuba
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:target |
immune system
|
| gptkbp:therapeuticArea |
autoimmune diseases
inflammatory diseases |
| gptkbp:bfsParent |
gptkb:CIGB-258
|
| gptkbp:bfsLayer |
7
|